Related Experiment Video
Updated: Dec 9, 2025
Preparation of Human Myocardial Tissue for Long-Term Cultivation
Published on: June 2, 2022
An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia
Chandan Takkar1, Tareq Nassar2, Wajeh Qunibi3
1Internal Medicine, Division of Nephrology, University of Texas Health Science Center at San Antonio , San Antonio, USA.
Insights
New potassium binders, sodium zirconium cyclosilicate (SZC) and patiromer, offer effective treatment for hyperkalemia in patients with chronic kidney disease, diabetes, and heart failure. These agents facilitate RAAS inhibitor use, improving renal and cardiac protection.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hyperkalemia (serum potassium > 5.0 mEq/l) increases mortality risk and is common in CKD, DM, and HF patients, especially those on RAAS inhibitors.
- RAAS inhibitors offer renal and cardiac benefits but are often limited by hyperkalemia, leading to suboptimal dosing or discontinuation.
- Chronic hyperkalemia management has been challenging, but new potassium-binding resins have emerged as a significant advancement.
Purpose of the Study:
- To review clinical data on the pharmacokinetics, efficacy, and safety of sodium zirconium cyclosilicate (SZC) for hyperkalemia treatment.
- To evaluate SZC's role in managing hyperkalemia in patients with comorbidities like CKD, DM, and HF.
- To assess how SZC facilitates the continued use of beneficial RAAS inhibitors.
Main Methods:
- Review of key clinical data on sodium zirconium cyclosilicate (SZC).
- Analysis of pharmacokinetic, efficacy, and safety profiles from relevant studies.
- Examination of randomized clinical trial data regarding SZC's potassium-lowering effects.
Main Results:
- Sodium zirconium cyclosilicate (SZC) effectively lowers serum potassium levels.
- SZC helps maintain normokalemia in the majority of treated hyperkalemic patients.
- Clinical trials demonstrate SZC lowers potassium within 1 hour, though it's not indicated for acute hyperkalemia.
Conclusions:
- SZC and patiromer are promising agents for managing hyperkalemia in patients with CKD, DM, and HF.
- These novel therapies enable sustained use of RAAS inhibitors, crucial for renal and cardiac protection.
- SZC is well-tolerated with minimal adverse effects, offering a valuable new option for chronic hyperkalemia.
Introduction:
Hyperkalemia, defined as serum potassium level > 5.0 mEq/l, is associated with serious cardiac dysrhythmias, sudden death and increased mortality risk. It is common in patients with chronic kidney disease (CKD), diabetes (DM) and heart failure (HF), particularly in those treated with the renin-angiotensin-aldosterone system (RAAS) inhibitors or potassium-sparing diuretics. Although these drugs have documented renal and cardiac protective benefits, frequent hyperkalemia associated with their use often dictates administration of suboptimal doses or their discontinuation altogether. Treatment for chronic hyperkalemia in these settings has been challenging; however, the recent introduction of two new potassium-binding resins has revolutionized our approach to treating hyperkalemia.
Areas Covered:
We review key clinical data relating to the pharmacokinetics, efficacy and safety of sodium zirconium cyclosilicate (SZC) as a treatment option for hyperkalemia.
Expert Opinion:
SZC and Patiromer are promising new agents for lowering serum potassium in hyperkalemic patients, including those with CKD, with and without DM or HF, facilitating the use of the RAAS inhibitors for renal and cardiac protection. Recent randomized clinical trials have shown that SZC effectively lowers serum potassium and maintains normokalemia in most hyperkalemic patients. Clinical trials showed that SZC lowers serum potassium within 1 h, although it is not approved for treating acute hyperkalemia. SZC was well tolerated and associated with minimal adverse effects.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:26Regulation of Sodium and Potassium
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...